ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BƯỚC ĐẦU BỆNH NHÂN UNG THƯ DẠ DÀY GIAI ĐOẠN MUỘN BẰNG PHÁC ĐỒ XELOX TẠI BỆNH VIỆN K

Abstract

Objective: Evaluate the clinical and paraclinical treatment response of patients with late-stage gastric cancer treated with the XELOX regimen. Patients and methods: Cross-sectional descriptive study on 52 patients with a confirmed diagnosis of late-stage gastric cancer, no longer amenable to radical surgery, treated with the XELOX regimen at the hospital, at Vietnam National Cancer Hospital from June 2016 to March 2020. Compare proportions: use the χ2 test (p<0,05) to test statistical significance. Results: The overall response rate reached 48,1%, in which 3,9% of patients (n=2) achieved a complete response and 44,2% of patients (n=23) achieved a partial response. The disease remained stable in 23,1% (n=12) of patients. There were 28,8% of patients (n=15) with progressive disease. After treatment, most of the clinical symptoms and PS improved significantly compared to before treatment (p<0,05). The response rate of the group of patients treated with the standard dose was 62,5%, significantly higher than the group of patients treated with less than the standard dose was 35,7% (p < 0,05). Conclusion: XELOX regimen treatment in patients with late-stage gastric cancer helps improve clinical symptoms and the overall objective response rate was 48,1%, in which patients treated with standard dose had a lower rate of Response was significantly higher than in patients treated with substandard doses.